Paul Hudson (AP Images)
January 11, 2021 03:12 AM EST
Deals

Sanofi CEO Paul Hud­son’s lat­est M&A gam­bit adds new eczema drug in $1.5B buy­out. And he’s steer­ing back in­to a mar­ket mael­strom

John Carroll

Editor & Founder

Around the same time that Sanofi CEO Paul Hud­son was en­gi­neer­ing a $3.7 bil­lion buy­out of Prin­cip­ia to add a late-stage mul­ti­ple scle­ro­sis drug to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

J&J re­ports dura­bil­i­ty da­ta for blad­der can­cer 'pret­zel' drug af­ter FDA fil­ing

Paul Stof­fels on re­tir­ing from Gala­pa­gos; Boehringer In­gel­heim switch­es up lead­er­ship

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times